Education
About Us
Working with TipRanks
Follow Us
Galecto (GLTO)
NASDAQ:GLTO
GLTO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.01 - $15.15
Previous CloseN/A
Volume2.41K
Average Volume (3M)21.67K
Market Cap
$4.99M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.06
Next Earnings
Oct 31, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,322,359
10 Day Avg. Volume34,489
30 Day Avg. Volume21,674
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$10.00Price Target Upside178.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Galecto News
GLTO FAQ
What was Galecto’s price range in the past 12 months?
Galecto lowest stock price was $2.01 and its highest was $15.15 in the past 12 months.
What is Galecto’s market cap?
Galecto’s market cap is $4.99M.
When is Galecto’s upcoming earnings report date?
Galecto’s upcoming earnings report date is Oct 31, 2025 which is in 92 days.
How were Galecto’s earnings last quarter?
Currently, no data Available
Is Galecto overvalued?
According to Wall Street analysts Galecto’s price is currently Undervalued.
Does Galecto pay dividends?
Galecto does not currently pay dividends.
What is Galecto’s EPS estimate?
Galecto’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Galecto have?
Galecto has 1,322,359 shares outstanding.
What happened to Galecto’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Galecto?
Currently, no hedge funds are holding shares in GLTO
Company Description
Galecto
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
Technical Analysis
Matinas BioPharma
―
Quoin Pharmaceuticals
―
Silo Pharma
―
GRI Bio
―
Conduit Pharmaceuticals
―
Ownership Overview
2.66% Insiders
1.42% Mutual Funds
7.56% Other Institutional Investors
87.72% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---